Veea loses independent director; falls out of Nasdaq governance compliance
Veea Inc. notified Nasdaq on June 2, 2026, that it no longer meets independent director requirements after the passing of board member Douglas Maine on June 1, 2026. The company's six-member board now has only three independent directors, falling short of Nasdaq rules for board composition and committee staffing. Nasdaq granted a cure period extending until the earlier of the company's next annual shareholder meeting or May 31, 2027 (or November 27, 2026 if that meeting occurs before then); the stock remains listed pending compliance restoration.
Key facts
- Douglas Maine, independent director on audit and compensation committees, passed away June 1, 2026
- Board size: 6 directors; independent directors: 3
- Audit committee now has only 2 independent directors (needs 3 under Nasdaq Rule 5605(c)(2)(A))
- Compensation committee now has only 1 independent director (needs 2 under Nasdaq Rule 5605(d)(2)(A))
- Cure period granted by Nasdaq letter dated June 3, 2026
- Cure deadline: earlier of next annual meeting or May 31, 2027; or November 27, 2026 if annual meeting held before that date
- Common stock and public warrants trade under symbols VEEA and VEEAW on Nasdaq Capital Market
Why it matters
Nasdaq compliance failures can lead to delisting if not cured within the specified period, which would materially affect the company's ability to trade publicly and raise capital.
Get the next chapter in your inbox — a Sentinel watches this company and briefs the next material filing the moment it lands.
Derived from Form 8-K filed June 4, 2026. Not investment advice. View the source filing on SEC.gov →